Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9220938 | Sleep Medicine | 2005 | 9 Pages |
Abstract
The significant improvements in sleep and daytime function were evident in those switched from double-blind placebo to 6 months of open-label eszopiclone therapy and were sustained during the 6 months of open-label treatment for those receiving prior double-blind eszopiclone. During 12 months of nightly treatment, eszopiclone 3Â mg was well tolerated; tolerance was not observed.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Thomas Roth, James K. Walsh, Andrew Krystal, Thomas Wessel, Timothy A. Roehrs,